Skip to content
All news
Earnings

Schrodinger Q1 2026: Hosted Licensing Progress and ACV Growth Highlighted

Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results, highlighting progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations.

May 6, 2026
2 min read
Source: MarketBeat
Share:

Key Numbers

quarter
Q1 2026
acv growth
highlighted growth
hosted transition
progress in transition

Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results, highlighting progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations.

Key Financial Metrics

MetricQ1 2026
RevenueNot yet disclosed
Net IncomeNot yet disclosed
EPSNot yet disclosed
Annual Contract Value (ACV)Notable growth

Highlights from the Report

  • Hosted Licensing Transition: Schrodinger continues shifting from traditional licenses to a hosted model, providing recurring revenue streams.
  • ACV Growth: The company reported growth in annual contract value, a key indicator of subscription model success.
  • Business Development Activity: Drug discovery collaborations saw increased activity, strengthening the company's position in this area.

Future Guidance

Schrodinger did not provide specific numerical guidance for the next quarter but reaffirmed its commitment to continuing the hosted licensing transition and expanding its customer base.

Impact on Stock

SDGR stock did not show significant movement following the announcement, as investors await full financial details. The stock is trading at previous levels.

What This Means for Investors

The shift to hosted licensing is a positive step toward more stable recurring revenue. However, investors should wait for the complete financial report to assess performance accurately.

Frequently Asked Questions

The company highlighted progress in transitioning to hosted software licensing, growth in annual contract value (ACV), and increased business development activity in drug discovery.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.